[{"id":"bbb14559-9c9b-416f-a6ef-ec6e09093d8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04694846","created_at":"2024-05-18T04:23:56.024Z","updated_at":"2024-07-02T16:35:04.284Z","phase":"","brief_title":"Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use","source_id_and_acronym":"NCT04694846","lead_sponsor":"Thomas Jefferson University","biomarkers":" IL2 • IL10 • CRP","pipe":" | ","alterations":" IL2 expression","tags":["IL2 • IL10 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2 expression"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/19/2020","start_date":" 08/19/2020","primary_txt":" Primary completion: 08/16/2024","primary_completion_date":" 08/16/2024","study_txt":" Completion: 08/16/2024","study_completion_date":" 08/16/2024","last_update_posted":"2024-05-13"},{"id":"a8f4389e-834a-4aa3-a7a4-f6955f4bf261","acronym":"","url":"https://clinicaltrials.gov/study/NCT04438564","created_at":"2021-01-18T21:21:58.152Z","updated_at":"2024-07-02T16:35:56.179Z","phase":"","brief_title":"Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients","source_id_and_acronym":"NCT04438564","lead_sponsor":"China Medical University Hospital","biomarkers":" IFNG • TNFA • IL2","pipe":" | ","alterations":" IFNG expression • IL2 expression","tags":["IFNG • TNFA • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression • IL2 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 05/18/2020","start_date":" 05/18/2020","primary_txt":" Primary completion: 07/31/2023","primary_completion_date":" 07/31/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2023-02-08"},{"id":"b5ce9f6f-90bd-4e6c-8af0-4771e28aea48","acronym":"","url":"https://clinicaltrials.gov/study/NCT03021993","created_at":"2021-01-18T14:52:12.866Z","updated_at":"2025-02-25T14:37:08.309Z","phase":"Phase 2","brief_title":"Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer","source_id_and_acronym":"NCT03021993","lead_sponsor":"Medical University of South Carolina","biomarkers":" CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3","pipe":" | ","alterations":" CD8 expression • IFNG expression • IL2 expression","tags":["CD8 • IFNG • CD4 • CD69 • ICOS • IL10 • GZMB • TGFB1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • IFNG expression • IL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/30/2017","start_date":" 05/30/2017","primary_txt":" Primary completion: 11/15/2021","primary_completion_date":" 11/15/2021","study_txt":" Completion: 11/15/2021","study_completion_date":" 11/15/2021","last_update_posted":"2021-12-13"},{"id":"3e9f16ba-7ef3-4a62-bda2-2d123d6d52a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03965546","created_at":"2021-01-18T19:30:34.813Z","updated_at":"2024-07-02T16:36:57.170Z","phase":"Phase 1","brief_title":"ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer","source_id_and_acronym":"NCT03965546","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10","pipe":" | ","alterations":" HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression","tags":["HLA-A • IFNG • IL6 • TNFA • AFP • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • AFP expression • IL10 elevation • IL2 expression • IL6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • ET1402L1-ARTEMIS T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 27","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2019-08-08"},{"id":"3b7aa45c-07ba-4421-ad73-bd3b53ea28b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00425672","created_at":"2021-01-18T01:29:59.629Z","updated_at":"2024-07-02T16:37:04.882Z","phase":"Phase 1/2","brief_title":"ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment","source_id_and_acronym":"NCT00425672","lead_sponsor":"University of Washington","biomarkers":" IL2RA","pipe":" | ","alterations":" IL2RA expression • IL2 expression","tags":["IL2RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression • IL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 09/01/2005","start_date":" 09/01/2005","primary_txt":" Primary completion: 04/01/2010","primary_completion_date":" 04/01/2010","study_txt":"","study_completion_date":"","last_update_posted":"2018-12-05"}]